Associations of prenatal stress with 5-year-old children?s executive function in a low socioeconomic status population / Daphne M. VRANTSIDIS in Development and Psychopathology, 37-2 (May 2025)  

Public ISBD [article]  inDevelopment and Psychopathology > 37-2 (May 2025) . - p.1044-1053 Titre : Associations of prenatal stress with 5-year-old children?s executive function in a low socioeconomic status population Type de document : texte imprimé Auteurs : Daphne M. VRANTSIDIS, Auteur ; Mark A. KLEBANOFF, Auteur ; Keith Owen YEATES, Auteur ; Aaron MURNAN, Auteur ; Peter FRIED, Auteur ; Kelly M. BOONE, Auteur ; Joseph R. RAUSCH, Auteur ; Sarah A. KEIM, Auteur Article en page(s) : p.1044-1053 Langues : Anglais (eng) Mots-clés : early childhood  executive function  pregnancy  prenatal stress  sex differences  socioeconomic status Index. décimale : PER Périodiques Résumé : Prenatal stress has a significant, but small, negative effect on children s executive function (EF) in middle and high socioeconomic status (SES) households. Importantly, rates and severity of prenatal stress are higher and protective factors are reduced in lower SES households, suggesting prenatal stress may be particularly detrimental for children s EF in this population. This study examined whether prenatal stress was linked to 5-year-old?s EF in a predominantly low SES sample and child sex moderated this association, as males may be more vulnerable to adverse prenatal experiences. Participants were 132 mother-child dyads drawn from a prospective prenatal cohort. Mothers reported on their depression symptoms, trait anxiety, perceived stress, everyday discrimination, and sleep quality at enrollment and once each trimester, to form a composite prenatal stress measure. Children s EF was assessed at age 5 years using the parent-report Behavior Rating Inventory of Executive Function - Preschool (BRIEF-P) Global Executive Composite subscale and neuropsychological tasks completed by the children. Mixed models revealed higher prenatal stress was associated with lower BRIEF-P scores, indicating better EF, for females only. Higher prenatal stress was associated with lower performance on neuropsychological EF measures for both males and females. Results add to the limited evidence about prenatal stress effects on children s EF in low SES households. En ligne : https://dx.doi.org/10.1017/S0954579424000890 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=552 [article] Associations of prenatal stress with 5-year-old children?s executive function in a low socioeconomic status population [texte imprimé] / Daphne M. VRANTSIDIS, Auteur ; Mark A. KLEBANOFF, Auteur ; Keith Owen YEATES, Auteur ; Aaron MURNAN, Auteur ; Peter FRIED, Auteur ; Kelly M. BOONE, Auteur ; Joseph R. RAUSCH, Auteur ; Sarah A. KEIM, Auteur . - p.1044-1053. Langues : Anglais (eng) in Development and Psychopathology > 37-2 (May 2025) . - p.1044-1053 Mots-clés : early childhood  executive function  pregnancy  prenatal stress  sex differences  socioeconomic status Index. décimale : PER Périodiques Résumé : Prenatal stress has a significant, but small, negative effect on children s executive function (EF) in middle and high socioeconomic status (SES) households. Importantly, rates and severity of prenatal stress are higher and protective factors are reduced in lower SES households, suggesting prenatal stress may be particularly detrimental for children s EF in this population. This study examined whether prenatal stress was linked to 5-year-old?s EF in a predominantly low SES sample and child sex moderated this association, as males may be more vulnerable to adverse prenatal experiences. Participants were 132 mother-child dyads drawn from a prospective prenatal cohort. Mothers reported on their depression symptoms, trait anxiety, perceived stress, everyday discrimination, and sleep quality at enrollment and once each trimester, to form a composite prenatal stress measure. Children s EF was assessed at age 5 years using the parent-report Behavior Rating Inventory of Executive Function - Preschool (BRIEF-P) Global Executive Composite subscale and neuropsychological tasks completed by the children. Mixed models revealed higher prenatal stress was associated with lower BRIEF-P scores, indicating better EF, for females only. Higher prenatal stress was associated with lower performance on neuropsychological EF measures for both males and females. Results add to the limited evidence about prenatal stress effects on children s EF in low SES households. En ligne : https://dx.doi.org/10.1017/S0954579424000890 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=552

Effect of Omega-3 and -6 Supplementation on Language in Preterm Toddlers Exhibiting Autism Spectrum Disorder Symptoms / Kelly W. SHEPPARD in Journal of Autism and Developmental Disorders, 47-11 (November 2017)  

Public ISBD [article]  inJournal of Autism and Developmental Disorders > 47-11 (November 2017) . - p.3358-3369 Titre : Effect of Omega-3 and -6 Supplementation on Language in Preterm Toddlers Exhibiting Autism Spectrum Disorder Symptoms Type de document : texte imprimé Auteurs : Kelly W. SHEPPARD, Auteur ; Kelly M. BOONE, Auteur ; Barbara GRACIOUS, Auteur ; Mark A. KLEBANOFF, Auteur ; Lynette K. ROGERS, Auteur ; Joseph R. RAUSCH, Auteur ; Christopher BARTLETT, Auteur ; Daniel L. COURY, Auteur ; Sarah A. KEIM, Auteur Article en page(s) : p.3358-3369 Langues : Anglais (eng) Mots-clés : Autism spectrum disorder  Children born preterm  Language development  MacArthur Bates communicative development inventory  Omega-3 fatty acids  Omega-6 fatty acids Index. décimale : PER Périodiques Résumé : Delayed language development may be an early indicator of autism spectrum disorder (ASD). Early intervention is critical for children with ASD, and the present study presents pilot data on a clinical trial of omega-3 and -6 fatty acid supplementation and language development, a secondary trial outcome, in children at risk for ASD. We randomized 31 children to receive an omega-3 and -6 supplement or a placebo for 3 months, and measured their language abilities at baseline and after supplementation. Gesture use, but not word production, increased for children in the treatment group more than children in the placebo group. These results suggest possible effectiveness of omega-3 and -6 supplementation for language development in children at risk for ASD. En ligne : http://dx.doi.org/10.1007/s10803-017-3249-3 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=324 [article] Effect of Omega-3 and -6 Supplementation on Language in Preterm Toddlers Exhibiting Autism Spectrum Disorder Symptoms [texte imprimé] / Kelly W. SHEPPARD, Auteur ; Kelly M. BOONE, Auteur ; Barbara GRACIOUS, Auteur ; Mark A. KLEBANOFF, Auteur ; Lynette K. ROGERS, Auteur ; Joseph R. RAUSCH, Auteur ; Christopher BARTLETT, Auteur ; Daniel L. COURY, Auteur ; Sarah A. KEIM, Auteur . - p.3358-3369. Langues : Anglais (eng) in Journal of Autism and Developmental Disorders > 47-11 (November 2017) . - p.3358-3369 Mots-clés : Autism spectrum disorder  Children born preterm  Language development  MacArthur Bates communicative development inventory  Omega-3 fatty acids  Omega-6 fatty acids Index. décimale : PER Périodiques Résumé : Delayed language development may be an early indicator of autism spectrum disorder (ASD). Early intervention is critical for children with ASD, and the present study presents pilot data on a clinical trial of omega-3 and -6 fatty acid supplementation and language development, a secondary trial outcome, in children at risk for ASD. We randomized 31 children to receive an omega-3 and -6 supplement or a placebo for 3 months, and measured their language abilities at baseline and after supplementation. Gesture use, but not word production, increased for children in the treatment group more than children in the placebo group. These results suggest possible effectiveness of omega-3 and -6 supplementation for language development in children at risk for ASD. En ligne : http://dx.doi.org/10.1007/s10803-017-3249-3 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=324

Randomized Controlled Trial of Omega-3 and -6 Fatty Acid Supplementation to Reduce Inflammatory Markers in Children with Autism Spectrum Disorder / Sarah A. KEIM in Journal of Autism and Developmental Disorders, 52-12 (December 2022)  

Public ISBD [article]  inJournal of Autism and Developmental Disorders > 52-12 (December 2022) . - p.5342-5355 Titre : Randomized Controlled Trial of Omega-3 and -6 Fatty Acid Supplementation to Reduce Inflammatory Markers in Children with Autism Spectrum Disorder Type de document : texte imprimé Auteurs : Sarah A. KEIM, Auteur ; Abigail JUDE, Auteur ; Katie SMITH, Auteur ; Aiman Q. KHAN, Auteur ; Daniel L. COURY, Auteur ; Joseph R. RAUSCH, Auteur ; Shivika UDAIPURIA, Auteur ; Megan NORRIS, Auteur ; Lindsay R. BARTRAM, Auteur ; Anita R. NARAYANAN, Auteur ; Lynette K. ROGERS, Auteur Année de publication : 2022 Article en page(s) : p.5342-5355 Langues : Anglais (eng) Mots-clés : Child  Child, Preschool  Humans  Autism Spectrum Disorder/drug therapy  Biomarkers  Dietary Supplements  Double-Blind Method  Fatty Acids, Omega-3/therapeutic use  Fatty Acids, Omega-6/therapeutic use  Interleukin-2/metabolism  Autism spectrum disorder  Il-2  Inflammation  Omega-3 fatty acids  Omega-6 fatty acids  Young child  the content of this article. The content is solely the responsibility of the  authors and does not necessarily represent the official views of the National  Institutes of Health. Nordic Naturals provided the investigational product at no  cost  and Welsh, Holme, & Clark Co., Inc. provided canola oil at no cost. Neither  the study sponsors nor product providers had a role in the study design  the  collection, analysis, and interpretation of data  writing of this report  or the  decision to submit the manuscript for publication. Index. décimale : PER Périodiques Résumé : This double-blind, randomized controlled trial, tested fatty acid (FA) supplementation in children (ages 2- < 6 years) recently diagnosed with Autism Spectrum Disorder (ASD). Participants received daily oral FA supplement containing omega-3 and omega-6 FA, or a placebo for 90 days based on participant weight. Erythrocyte FAs and the cytokines, IL-1ÃŽ2, IL-2, IFNÃŽ3, were measured in plasma obtained from serial blood collections. Treatment increased omega-3 and omega-6 FA levels (1.40 mol% for EPA and 1.62 mol% for DHA) and reduced IL-2 levels compared to placebo (- 0.17 pg/mL, 95% CI - 0.31, - 0.02, d=- 0.62). Omega 3-6 treatment was tolerable and adherence was greater than 70%. Future research will assess the effects of Omega 3-6 treatment on ASD symptoms. Registered on 06/08/2018 with ClinicalTrials.gov: NCT03550209. En ligne : http://dx.doi.org/10.1007/s10803-021-05396-9 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=489 [article] Randomized Controlled Trial of Omega-3 and -6 Fatty Acid Supplementation to Reduce Inflammatory Markers in Children with Autism Spectrum Disorder [texte imprimé] / Sarah A. KEIM, Auteur ; Abigail JUDE, Auteur ; Katie SMITH, Auteur ; Aiman Q. KHAN, Auteur ; Daniel L. COURY, Auteur ; Joseph R. RAUSCH, Auteur ; Shivika UDAIPURIA, Auteur ; Megan NORRIS, Auteur ; Lindsay R. BARTRAM, Auteur ; Anita R. NARAYANAN, Auteur ; Lynette K. ROGERS, Auteur . - 2022 . - p.5342-5355. Langues : Anglais (eng) in Journal of Autism and Developmental Disorders > 52-12 (December 2022) . - p.5342-5355 Mots-clés : Child  Child, Preschool  Humans  Autism Spectrum Disorder/drug therapy  Biomarkers  Dietary Supplements  Double-Blind Method  Fatty Acids, Omega-3/therapeutic use  Fatty Acids, Omega-6/therapeutic use  Interleukin-2/metabolism  Autism spectrum disorder  Il-2  Inflammation  Omega-3 fatty acids  Omega-6 fatty acids  Young child  the content of this article. The content is solely the responsibility of the  authors and does not necessarily represent the official views of the National  Institutes of Health. Nordic Naturals provided the investigational product at no  cost  and Welsh, Holme, & Clark Co., Inc. provided canola oil at no cost. Neither  the study sponsors nor product providers had a role in the study design  the  collection, analysis, and interpretation of data  writing of this report  or the  decision to submit the manuscript for publication. Index. décimale : PER Périodiques Résumé : This double-blind, randomized controlled trial, tested fatty acid (FA) supplementation in children (ages 2- < 6 years) recently diagnosed with Autism Spectrum Disorder (ASD). Participants received daily oral FA supplement containing omega-3 and omega-6 FA, or a placebo for 90 days based on participant weight. Erythrocyte FAs and the cytokines, IL-1ÃŽ2, IL-2, IFNÃŽ3, were measured in plasma obtained from serial blood collections. Treatment increased omega-3 and omega-6 FA levels (1.40 mol% for EPA and 1.62 mol% for DHA) and reduced IL-2 levels compared to placebo (- 0.17 pg/mL, 95% CI - 0.31, - 0.02, d=- 0.62). Omega 3-6 treatment was tolerable and adherence was greater than 70%. Future research will assess the effects of Omega 3-6 treatment on ASD symptoms. Registered on 06/08/2018 with ClinicalTrials.gov: NCT03550209. En ligne : http://dx.doi.org/10.1007/s10803-021-05396-9 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=489

---

1 (1 - 3 / 3) Par page : 25 50 100 200